British Journal of Cancer The B<em>ritish Journal of Cancer</em> is one of the most-cited general cancer journals, publishing significant advances in translational and clinical cancer research. It also publishes high-quality reviews and thought-provoking comment on all aspects of cancer prevention, diagnosis and treatment. BJC welcomes research across all cancer types and has a particular focus on: metastasis, microenvironment, immunology and immunotherapy, targeted and next-generation therapeutics, chemotherapy and radiotherapy, mechanisms of resistance, clinical trials, genomics, epigenomics and precision medicine, epidemiology, metabolism and state-of-the art diagnostic approaches. The B<em>ritish Journal of Cancer </em>is published in association with Cancer Research UK. http://feeds.nature.com/bjc/rss/current Nature Publishing Group en © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. British Journal of Cancer © 2024 Macmillan Publishers Limited, part of Springer Nature. All rights reserved. permissions@nature.com British Journal of Cancer https://www.nature.com/uploads/product/bjc/rss.png http://feeds.nature.com/bjc/rss/current <![CDATA[Methylation analysis of <i>DCC</i> gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer]]> https://www.nature.com/articles/s41416-024-02654-2 British Journal of Cancer, Published online: 27 March 2024; doi:10.1038/s41416-024-02654-2

Methylation analysis of DCC gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer]]>
DCC gene in saliva samples is an efficient method for non-invasive detection of superficial hypopharyngeal cancer]]> Ryosuke HiraiHideaki KinugasaShumpei YamamotoSoichiro AkoKoichiro TsutsumiMakoto AbeKoji MiyaharaMasahiro NakagawaMotoyuki Otsuka doi:10.1038/s41416-024-02654-2 British Journal of Cancer, Published online: 2024-03-27; | doi:10.1038/s41416-024-02654-2 2024-03-27 British Journal of Cancer 10.1038/s41416-024-02654-2 https://www.nature.com/articles/s41416-024-02654-2
<![CDATA[Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients]]> https://www.nature.com/articles/s41416-024-02659-x British Journal of Cancer, Published online: 26 March 2024; doi:10.1038/s41416-024-02659-x

Extending the dosing intervals of nivolumab: model-based simulations in unselected cancer patients]]>
Alicja PuszkielGuillaume BianconiBlaise PasquiersDavid BalakirouchenaneJennifer ArrondeauPascaline Boudou-RouquetteMarie-Claire BretagneJoe-Elie SalemXavier DeclèvesMichel VidalNora KramkimelSarah GueganSelim AractingiOlivier HuillardJérôme AlexandreMarie WislezFrançois GoldwasserBenoit Blanchet doi:10.1038/s41416-024-02659-x British Journal of Cancer, Published online: 2024-03-26; | doi:10.1038/s41416-024-02659-x 2024-03-26 British Journal of Cancer 10.1038/s41416-024-02659-x https://www.nature.com/articles/s41416-024-02659-x
<![CDATA[Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications]]> https://www.nature.com/articles/s41416-024-02607-9 British Journal of Cancer, Published online: 26 March 2024; doi:10.1038/s41416-024-02607-9

Incidental pathogenic germline alterations detected through liquid biopsy in patients with solid tumors: prevalence, clinical utility and implications]]>
Juan Carlos LagunaBelén PastorIrene NaldaSara Hijazo-PecheroCristina TeixidoMiriam PotronyJoan Antón Puig-ButilléLaura Mezquita doi:10.1038/s41416-024-02607-9 British Journal of Cancer, Published online: 2024-03-26; | doi:10.1038/s41416-024-02607-9 2024-03-26 British Journal of Cancer 10.1038/s41416-024-02607-9 https://www.nature.com/articles/s41416-024-02607-9
<![CDATA[Identification of unique rectal cancer-specific subtypes]]> https://www.nature.com/articles/s41416-024-02656-0 British Journal of Cancer, Published online: 26 March 2024; doi:10.1038/s41416-024-02656-0

Identification of unique rectal cancer-specific subtypes]]>
Batuhan KisakolAnna MatveevaManuela SalvucciAlexander KelElizabeth McDonoughFiona GintyDaniel B. LongleyJochen H. M. Prehn doi:10.1038/s41416-024-02656-0 British Journal of Cancer, Published online: 2024-03-26; | doi:10.1038/s41416-024-02656-0 2024-03-26 British Journal of Cancer 10.1038/s41416-024-02656-0 https://www.nature.com/articles/s41416-024-02656-0
<![CDATA[Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma]]> https://www.nature.com/articles/s41416-024-02661-3 British Journal of Cancer, Published online: 22 March 2024; doi:10.1038/s41416-024-02661-3

Combination of EZH2 and ATM inhibition in BAP1-deficient mesothelioma]]>
Nick LandmanDanielle HulsmanJitendra BadhaiJawahar KopparamJulian PuppeGaurav Kumar PandeyMaarten van Lohuizen doi:10.1038/s41416-024-02661-3 British Journal of Cancer, Published online: 2024-03-22; | doi:10.1038/s41416-024-02661-3 2024-03-22 British Journal of Cancer 10.1038/s41416-024-02661-3 https://www.nature.com/articles/s41416-024-02661-3
<![CDATA[Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer]]> https://www.nature.com/articles/s41416-024-02610-0 British Journal of Cancer, Published online: 22 March 2024; doi:10.1038/s41416-024-02610-0

Persistence of peripheral CD8 + CD28− T cells indicates a favourable outcome and tumour immunity in first-line HER2-positive metastatic breast cancer]]>
Xiaoran LiuXiangming ChengFeng XieKun LiYongcan ShiBin ShaoXu LiangFengling WanShidong JiaYue ZhangYiqiang LiuHuiping Li doi:10.1038/s41416-024-02610-0 British Journal of Cancer, Published online: 2024-03-22; | doi:10.1038/s41416-024-02610-0 2024-03-22 British Journal of Cancer 10.1038/s41416-024-02610-0 https://www.nature.com/articles/s41416-024-02610-0
<![CDATA[Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer]]> https://www.nature.com/articles/s41416-024-02662-2 British Journal of Cancer, Published online: 22 March 2024; doi:10.1038/s41416-024-02662-2

Association of immune-related adverse events with durvalumab efficacy after chemoradiotherapy in patients with unresectable Stage III non-small cell lung cancer]]>
Koji HarataniAtsushi NakamuraNobuaki MamesayaKenji SawaYoshimasa ShiraishiRyota SaitoJunko TanizakiYosuke TamuraAkito HataKosuke TsurunoTomohiro SakamotoShunsuke TeraokaMasahide OkiHiroshi WatanabeTakaaki TokitoKenji NagataTakeshi MasudaYasushi NakamuraKazuko SakaiYasutaka ChibaAkihiko ItoKazuto NishioNobuyuki YamamotoKazuhiko NakagawaHidetoshi Hayashi doi:10.1038/s41416-024-02662-2 British Journal of Cancer, Published online: 2024-03-22; | doi:10.1038/s41416-024-02662-2 2024-03-22 British Journal of Cancer 10.1038/s41416-024-02662-2 https://www.nature.com/articles/s41416-024-02662-2
<![CDATA[Radiation therapy with phenotypic medicine: towards N-of-1 personalization]]> https://www.nature.com/articles/s41416-024-02653-3 British Journal of Cancer, Published online: 21 March 2024; doi:10.1038/s41416-024-02653-3

Radiation therapy with phenotypic medicine: towards N-of-1 personalization]]>
Li Ming ChongPeter WangV. Vien LeeSmrithi VijayakumarHong Qi TanFu Qiang WangTeri Danielle You Ying YeohAnh T. L. TruongLester Wen Jeit TanShi Bei TanKirthika Senthil KumarEric HauBalamurugan A. VellayappanAgata BlasiakDean Ho doi:10.1038/s41416-024-02653-3 British Journal of Cancer, Published online: 2024-03-21; | doi:10.1038/s41416-024-02653-3 2024-03-21 British Journal of Cancer 10.1038/s41416-024-02653-3 https://www.nature.com/articles/s41416-024-02653-3